Skin Infection News and Research

RSS

Duke University is awarded $2M to initiate new clinical research network on antibacterial resistance

Duke University, Durham, N.C., has been awarded $2 million to initiate a new clinical research network focused on antibacterial resistance. Total funding for the leadership group cooperative agreement award could reach up to $62 million through 2019.

4 Jun 2013

Tafinlar, Mekinist get FDA approval to treat patients with advanced melanoma

The U.S. Food and Drug Administration today approved two new drugs, Tafinlar (dabrafenib) and Mekinist (trametinib), for patients with advanced (metastatic) or unresectable (cannot be removed by surgery) melanoma, the most dangerous type of skin cancer.

30 May 2013

University of Granada researchers patent new treatment for acne

University of Granada scientists have patented a new treatment for acne that is based on completely natural substances and is much more effective than artificial formulas because it does not create resistance to bacteria and has no secondary effects.

23 May 2013

Certain varieties of clay have ability to kill MRSA, says ASU researcher

In the race to protect society from infectious microbes, the bugs are outrunning us. The need for new therapeutic agents is acute, given the emergence of novel pathogens as well as old foes bearing heightened antibiotic resistance.

20 May 2013

Sorrento Therapeutics' anti-MRSA program gets NIAID support

Sorrento Therapeutics, Inc. announced today that its Fast-Track Advanced Technology Small Business Technology Transfer Research grant (#1R42AI098182-02) from the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health, supporting the development of novel human antibody therapeutics to combat Staphylococcus aureus (S. aureus or Staph) infections, including methicillin-resistant S. aureus, was renewed for the second year of a two year Phase I grant award.

18 May 2013

Researchers urge doctors to consider Lyme disease as cause when presented with skin lesions

When a person contracts Lyme disease, quick diagnosis and treatment are essential to avoiding long term complications. But the diagnostic process may be delayed if a physician does not recognize a skin rash caused by Lyme disease because it does not have the bull's-eye appearance that is best known to physicians and the public.

23 Apr 2013

Positive results from Affinium Pharmaceuticals' Phase 2a clinical trial of AFN-1252 in ABSSSI

Affinium Pharmaceuticals announced today that its Phase 2a clinical trial evaluating oral AFN-1252 in acute bacterial skin & skin structure infections demonstrated excellent efficacy and safety data, marking a significant proof-of-concept milestone for Affinium's first-in-class, novel antibiotic targeted against bacterial fatty acid biosynthesis inhibition (FabI inhibitors).

21 Mar 2013

International nonproprietary name “auriclosene” approved by WHO for NovaBay’s NVC-422

NovaBay® Pharmaceuticals, Inc. (NYSE MKT: NBY), a biotechnology company focused on addressing the large unmet therapeutic needs of the global anti-infective market with first-in-class compounds such as its proprietary Aganocides®, today announced that the World Health Organization (WHO) has approved the international nonproprietary name (INN) “auriclosene” (pronounced awr-rih-CLO-zeen) for the Company’s lead Aganocide® compound NVC-422.

21 Feb 2013

Researchers ESTABLISH efficacy of tedizolid phosphate for skin infections

Results from the phase III ESTABLISH-1 study show that the new antibiotic tedizolid phosphate is noninferior to linezolid for the treatment of acute bacterial and skin structure infections.

14 Feb 2013

IRHOM2-targeted drugs can effectively treat patients with rheumatoid arthritis

Researchers at Hospital for Special Surgery have identified a potential new target for drugs to treat patients with rheumatoid arthritis (RA), a protein known as IRHOM2. The finding could provide an effective and potentially less toxic alternative therapy to tumor necrosis factor-alpha blockers (TNF-blockers), the mainstay of treatment for rheumatoid arthritis, and could help patients who do not respond to this treatment. Efforts to develop drugs that hone in on this new target are underway.

28 Jan 2013

Institute of Bioengineering and Nanotechnology, IBM reveal new antimicrobial hydrogel

Researchers from IBM and the Institute of Bioengineering and Nanotechnology revealed today an antimicrobial hydrogel that can break through diseased biofilms and completely eradicate drug-resistant bacteria upon contact.

24 Jan 2013

Functionally deaf patients can gain normal hearing with new implant that replaces the middle ear

Functionally deaf patients can gain normal hearing with a new implant that replaces the middle ear. The unique invention from the Chalmers University of Technology has been approved for a clinical study. The first operation was performed on a patient in December 2012.

15 Jan 2013

Up to 1M people need food aid in Philippines areas hit by typhoon

"A month after Typhoon Bopha hit the southern Philippines, up to one million people need food assistance and thousands of others could be displaced for a second time, the United Nations says," AlertNet reports.

9 Jan 2013

Immune response more complicated than thought

Researchers have found that the orientation and concentration of antibodies could determine the control of bacterial infection.

28 Dec 2012

Certain UTI-causing bacteria become more difficult to treat with current antibiotics

Certain types of bacteria responsible for causing urinary tract infections (UTIs), the second-most-common infection in the United States, are becoming more difficult to treat with current antibiotics, according to new research from Extending the Cure (ETC), a project of the Center for Disease Dynamics, Economics & Policy.

14 Nov 2012

Proton pump inhibitors does not lead to higher rates of pneumonia

Previous studies that have associated the use of proton pump inhibitors (PPI) - which include popular anti-heartburn medications like Prilosec and Nexium - with an increased incidence of pneumonia may not have found a true cause-and-effect relationship.

2 Oct 2012

Autologous skin grafts heal chronic foot ulcers

Scientists have successfully treated chronic diabetic foot ulcers using skin grafts grown from individual patient cell samples.

13 Sep 2012

Antibiotics: facts and fictions: an interview with Dr Philippa Binns, clinical adviser at NPS MedicineWise

Antibiotics are medicines used to treat infections or diseases caused by bacteria, such as some respiratory tract infections (including pneumonia and whooping cough), urinary tract infections, skin infections and infected wounds.

6 Sep 2012

Trudeau Institute study holds promise for improved prevention and treatment of bacterial infections

New research from the laboratory of Dr. Andrea Cooper at the Trudeau Institute, just published in the European Journal of Immunology, holds promise for the improved prevention and treatment of bacterial infections and the life-threatening complications of chronic inflammation that can result from them.

29 Aug 2012

Infectious disease rates are high among homeless people

Rates of the infectious diseases HIV, Hepatitis C and tuberculosis among the world’s homeless people are many times higher than in the general population, according to a new systematic review of existing data published Online First in The Lancet Infectious Diseases.

20 Aug 2012